NASDAQ: CYTK
Cytokinetics Inc Stock

$30.48-0.99 (-3.15%)
Updated Jan 25, 2022
CYTK Price
$30.48
Fair Value Price
$31.61
Market Cap
$2.56B
52 Week Low
$17.72
52 Week High
$47.90
P/E
-9.83x
P/B
10.27x
P/S
133.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$21.55M
Earnings
-$228.67M
Gross Margin
100%
Operating Margin
-985.77%
Profit Margin
-1,061.1%
Debt to Equity
2.32
Operating Cash Flow
-$46M
Beta
1.05
Next Earnings
Feb 23, 2022
Ex-Dividend
N/A
Next Dividend
N/A

CYTK Overview

Zen Score

High
Medium
Low
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYTK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYTK ($30.48) is undervalued by 3.57% relative to our estimate of its Fair Value price of $31.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Valuation
CYTK is poor value based on its book value relative to its share price (10.27x), compared to the US Biotechnology industry average (4.53x)
Valuation
CYTK's cash and short-term investments... subscribe to Premium to read more.
Financials
There are 18 more CYTK due diligence checks available for Premium users.

CYTK News

Valuation

CYTK fair value

Fair Value of CYTK stock based on Discounted Cash Flow (DCF)
Price
$30.48
Fair Value
$31.61
Undervalued by
3.57%
CYTK ($30.48) is undervalued by... subscribe to Premium to read more.
Valuation

CYTK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-9.83x
Industry
21x
Market
33.66x

CYTK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
10.27x
Industry
4.53x
CYTK is poor value based... subscribe to Premium to read more.
Valuation

CYTK's financial health

Profit margin

Revenue
$5.4M
Net Income
-$76.1M
Profit Margin
-1,399.4%
CYTK's cash and short-term investments... subscribe to Premium to read more.
Financials
CYTK's profit margin has decreased... subscribe to Premium to read more.
Financials

Assets to liabilities

Assets
$827.5M
Liabilities
$578.5M
Debt to equity
2.32
CYTK's short-term assets ($494.94M) exceed... subscribe to Premium to read more.
Financials
CYTK's long-term liabilities ($497.65M) exceed... subscribe to Premium to read more.
Financials
CYTK's debt has increased relative... subscribe to Premium to read more.
Financials
CYTK's debt to equity ratio... subscribe to Premium to read more.
Financials

Cash flow

Operating
-$38.8M
Investing
-$208.7M
Financing
$300.9M
CYTK's cash and short-term investments... subscribe to Premium to read more.
Financials

Cytokinetics Stock FAQ

What is Cytokinetics's quote symbol?

(NASDAQ: CYTK) Cytokinetics trades on the NASDAQ under the ticker symbol CYTK. Cytokinetics stock quotes can also be displayed as NASDAQ: CYTK.

What is the 52 week high and low for Cytokinetics (NASDAQ: CYTK)?

(NASDAQ: CYTK) Cytokinetics's 52-week high was $47.90, and its 52-week low was $17.72. It is currently -36.37% from its 52-week high and 72.01% from its 52-week low.

How much is Cytokinetics stock worth today?

(NASDAQ: CYTK) Cytokinetics currently has 83,882,953 outstanding shares. With Cytokinetics stock trading at $30.48 per share, the total value of Cytokinetics stock (market capitalization) is $2.56B.

Cytokinetics stock was originally listed at a price of $97.56 in Apr 30, 2004. If you had invested in Cytokinetics stock at $97.56, your return over the last 17 years would have been -68.76%, for an annualized return of -6.61% (not including any dividends or dividend reinvestments).

How much is Cytokinetics's stock price per share?

(NASDAQ: CYTK) Cytokinetics stock price per share is $30.48 today (as of Jan 25, 2022).

What is Cytokinetics's Market Cap?

(NASDAQ: CYTK) Cytokinetics's market cap is $2.56B, as of Jan 26, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Cytokinetics's market cap is calculated by multiplying CYTK's current stock price of $30.48 by CYTK's total outstanding shares of 83,882,953.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.